Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
hepatitis A inactivated virus vaccine · 1 trial · 2 indications
CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer. Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained. Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type.
| Arm | Type | Description |
|---|---|---|
| Cervarix Group | EXPERIMENTAL | Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm. |
| Havrix Group | ACTIVE_COMPARATOR | Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm. |
| Name | Type | Description |
|---|---|---|
| human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | BIOLOGICAL | Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule |
| hepatitis A inactivated virus vaccine | BIOLOGICAL | Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule |
DISEASE CHARACTERISTICS: •Healthy participants * Deemed to be in good general health by history and physical examination •Resident of Guanacaste Province of Costa Rica and surrounding areas * Must remain a resident for ≥ 6 months after the first study vaccination PATIENT CHARACTERISTICS: Age ...
Top 20 of 27 competitors
Hepatitis A inactivated virus vaccine is being studied for the prevention of cervical cancer and precancerous conditions. It is an investigational vaccine evaluated in a Phase 3 clinical trial in healthy female participants aged 18 years and older.
Hepatitis A inactivated virus vaccine is a monoclonal antibody modality, though its specific molecular target is not disclosed. The vaccine is being investigated for its potential to prevent cervical intraepithelial neoplasia or cervical cancer in younger healthy participants.
Hepatitis A inactivated virus vaccine is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK.
Hepatitis A inactivated virus vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved for use. The Phase 3 trial has been completed.
Hepatitis A inactivated virus vaccine has one completed Phase 3 clinical trial, NCT00128661, titled "Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants." The trial enrolled 7,466 female participants in Costa Rica and was randomized, double-blind, and active-controlled.
Hepatitis A inactivated virus vaccine is being studied for the prevention of cervical cancer and precancerous conditions. In the clinical trial, it is compared against an active control, but no alternative names for the vaccine have been disclosed.